In April 2017, the Medicines Patent Pool (MPP) and Pharco Pharmaceuticals signed a licence and technology agreement for ravidasvir, an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes.

Country List
Algeria, Azerbaijan, Belarus, Djibouti, Egypt, Ethiopia, Iran (Islamic Republic of), Iraq, Jordan, Kazakhstan, Lebanon, Libya, Morocco, Russian Federation, Syrian Arab Republic, Tunisia, Ukraine, State of Palestine, Yemen